People diagnosed with early-stage Alzheimer’s disease now have two FDA-approved drugs, donanemab (Kisunla) and lecanemab (Leqembi), that can slow cognitive decline by targeting brain processes associated with the disease. These drugs, known as anti-amyloid antibodies, clear brain plaque deposits linked to Alzheimer’s symptoms. Donanemab recently received FDA approval, a year after lecanemab. Click here for article.
Mechanism of Action: Both drugs are anti-amyloid antibodies that clear brain plaques contributing to Alzheimer’s symptoms.
FDA Approval: Donanemab received FDA approval this month, while lecanemab was approved last year, marking the first new Alzheimer’s drugs in over 20 years.
Clinical Trials: Ongoing trials are testing whether these drugs can prevent Alzheimer’s in cognitively healthy individuals with early signs of amyloid plaques.
Administration and Side Effects: Both drugs are administered via infusions; donanemab monthly and lecanemab bi-weekly. Side effects include infusion site reactions, headaches, nausea, and amyloid-related imaging abnormalities (ARIA), which can involve serious brain swelling or bleeding.
Yorumlar